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Background: The treatment of locally recurrent endometrial cancer is based on limited evidence. The standard
treatment is radiotherapy (RT) which is effective for local control and the effect has been documented in pro-
spective studies. Investigations of surgical treatment (ST) of recurrences are few and limited to previously irra-
diated patients or patients with advanced disease. Investigation of surgical treatment for isolated vaginal vault
recurrence is practically nonexistent. The aim of this study is to evaluate the efﬁcacy of RT and ST in a non-
irradiated group with recurrent endometrial cancer limited to the vaginal vault.
Methods: Patients treated for recurrent endometrial cancer at Odense University Hospital, Denmark between
2003 and 2012 were identiﬁed, n = 118. Thirty-three patients had an isolated vaginal vault recurrence and
were treated with either RT, ST or both.
Re-recurrence rates and survival rates were calculated at 2 year follow-up using Fishers exact test.
Results: Twenty-six patients were treated with RT, 5 with ST, 2 with both. The mean (SD) follow-up-time was
4.4 years (2.99) (RT) and 3.9 years (0.90) (ST). Two year re-recurrence rates were 40% (RT) (95 CI 9.2–48%)
and 0% (ST) (95 CI 0–60%). Two-year survival rates were 83% (RT) (95 CI 71–100%) and 100% (ST) (95 CI 40–
100%) ST had one re-recurrence at 2.3 years.
Conclusion: This study indicates that ST is an appropriate treatment for locally recurrent endometrial cancer. Our
study involves a limited number of patients and is made retrospectively, therefore prospective and ideally
randomized trials evaluating both survival and complications are warranted.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Worldwide endometrial cancer is the ﬁfth most common cancer in
women. Furthermore, it is the most common gynecologic cancer in
developed countries (Cancer W.I.A.F.R.O., 2012). The continuing rise in
incidence is most likely explained by increased fat consumption and
obesity in developed countries and previous use of unopposed estro-
gens. Both are well recognized risk factors for endometrial cancer
(Amant et al., 2005).
Endometrial cancer is often detected in early stage because of
abnormal uterine bleeding which is the most frequent symptom.
Around 5–10% of women with this symptom are diagnosed with en-
dometrial cancer and the risk increases with age and other additional
risk factors (Gredmark et al., 1995).
Women diagnosed with endometrial cancer generally have a favor-
able prognosis. Seventy-ﬁve percent are diagnosed in FIGO stage I and
have a 5-year survival of 85%. Women diagnosed in FIGO stage II have
a 5-year survival of 75%, 40% for FIGO stage III and 20% for FIGO stage
IV (Amant et al., 2005; Danish Gynecological Cancer Group D, 2010).
Approximately 6–13% of all patients with endometrial cancer will de-
velop recurrent disease. The majority of the recurrences occur during
the ﬁrst 3 years after a primary disease and most of these are located
in the vaginal vault (Creutzberg et al., 2011; Huh et al., 2007).
In Denmark primary disease is surgically treated according to
national guidelines with total hysterectomy with bilateral salpingo-
oophorectomy including cytological examination of the peritoneal
ﬂuid. In grades 1 and 2 endometrioid adenocarcinomas (EAC) perop-
erative evaluation ofmyometrial invasion determines if lymph node ex-
cision is performed (performed if invasion exceeds 50%). In grade 3 EAC
and type 2 histology (serous, clear cell, undifferentiated carcinomas and
carcinosarcomas) it is performed without evaluation of myometrial in-
vasion. In stage II radical hysterectomy is performed. Patients with
type 2 histology furthermore have the omentum removed. FIGO stages
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III–IV are generally treated with adjuvant chemotherapy (Danish
Gynecological Cancer Group D, 2010). The patients in our department
are offered follow-up three times/year during the ﬁrst two years, then
twice a year on the third year after treatment for low risk primary can-
cer and for further 3 years in other groups (Danish Gynecological Cancer
Group D, 2010).
Recurrent disease is most often treated by radiotherapy which is in
accordance with recommendations in the international literature (van
Wijk et al., 2009). Surgical extirpation is in addition a valid andwell rec-
ognized treatment albeit not as common (van Wijk et al., 2009). To the
best of our knowledge publications describing the evidence for surgical
treatment of isolated vaginal vault recurrences of endometrial cancer in
non-irradiated patients do not exist.
At our department, the Department of Gynecology and Obstetrics at
Odense University Hospital (OUH), the treatment of recurrent disease
has been either surgery or radiotherapy at the discretion of the treating
gynae-oncologist.
In order to investigate potential differences in the outcome of radio-
therapy versus surgical treatment, we conducted a retrospective cohort
study based on patients treated for recurrent disease in the vaginal
vault.
Materials and method
All the patients treated for endometrial cancer at Odense University
Hospital, Odense, Denmark between January 1st 2003 and December
31st 2012 were identiﬁed in the electronic patient data system FPAS,
by searching for the diagnosis code DC549 cancer corporis uteri
(n = 896).
Patient records and pathology reports were examined to identify
those with recurrence of endometrial cancer.
Records from patients found to have recurrent disease were exam-
ined further and the following data recorded; date of birth, date of
death (or alive at follow up), date of primary cancer diagnosis, histolog-
ical type and grade of primary cancer, primary and adjuvant treatment
of primary cancer, FIGO stage (2009 revision), degree of myometrial in-
vasion, number and location of malignant and non-malignant lymph
nodes, and other metastases at the time of diagnosis. The date which
the recurrence was diagnosed, location of recurrence, treatment plus
neo-adjuvant and adjuvant treatments were recorded as were dates of
re-recurrences along with their size and location. Furthermore, data
regarding tumor size for the recurrences were collected.
For all included patients' dates of primary cancer diagnosis, recur-
rence and re-recurrence were veriﬁed by histological samples and
pathology reports. Follow up was conducted on April 1st, 2014.
The patients included were selected by these criteria 1) recurrence
of endometrial cancer in the period from January 1st 2003 to December
31st 2012 2) recurrence was local (vaginal vault or directly connected)
and 3) treatment was started with curative intent, either surgically or
with radiotherapy. Patients with distant metastases or recurrence on
the pelvic sidewall were excluded.
The radiotherapy treatment consisted primarily of external beam
radiation with a dosage of 50 Gy in 27 fractions and pulse dose rate
brachytherapy with a dosage of 15 Gy in 3 treatments. Surgical treat-
ment consisted of excision of tumor along with a border of tumor free
tissue. There were no cases in which bladder or bowel resection was
performed.
The palliative treatment chosen for the re-recurrences (n = 7) and
not cured ﬁrst recurrence (n = 2) in the radiotherapy group (all
re-recurrences including re-recurrences at 2 year follow-op) consisted
in three cases of endocrine treatment (aromatase inhibitors), one pa-
tient was in a too poor condition to receive any treatment, one patient
declined any treatment, three patients received chemotherapy with
Taxol and carboplatin, and in one case a patient received additional ra-
diotherapy against lung metastasis. The single re-recurrence in the
surgical treatment group was treated with Caelyx, a cytostatica of the
topoisomerase inhibitor group.
For comparison of our results regarding re-recurrence rate and
survival after surgical treatment of locally recurrent endometrial cancer,
we conducted a PubMed search in September 2014 using these terms:
endometrial cancer, endometrial carcinoma, uterine cancer, recurrence,
vaginal vault, vaginal recurrence, pelvic exenteration, surgical treat-
ment, and surgical resection.
The study was approved by the Danish Data Protection Agency.
Statistical analysis
As the number of included patients is only 33 with 5 in one group
(surgery), 26 in the other group (radiotherapy) and 2 patients receiving
combined treatment in a third group, we decided against elaborate sur-
vival analysis such as cox proportional hazards regression. The limited
number of data would not be able to give statistically meaningful and
valid results.
We conducted univariate analysis of risk factors using logrank test
and Cox regression for continuous variables.
We decided on a descriptive approach presenting the data using
Fisher's exact test to calculate re-recurrence and survival rates.
Re-recurrence rate and survival rates were calculated at 2 years of
follow-up.
Results
Fig. 1 presents the process of identifying the 33 patients included in
the analysis. All the patients were treated with curative intent; 26
received radiotherapy, 5 received surgical treatment and 2 received a
combination of treatment modalities.
Table 1 shows the number of all recurrences per year in the collected
material, and in which year the included patients had a recurrence.
Table 2 presents descriptive data on all 33 patients included in our
study. Two year follow-up data was available for all but ﬁve patients
in the radiotherapy group. These 5 patients are not included in the
two year rates. At the two year follow-up the 21 patients in the radio-
therapy group presented with the following outcomes; 15 patients
had no re-recurrence and 4 patients had re-recurrence of which 2
died within the 2 year follow-up. Two patients never became free of
896 patients found with 
endometrial cancer.
118 had a recurrence in 
the study time.
64 patients had central 
pelvic recurrence
54 non-central 
recurrence
31 received palliative 
treatment due to 
advanced disease or 
high comorbidity.
33 were treated with 
curative intent
26 recieved 
radiotherapy treatment
5 recieved surgical 
treatment
2 recieved a 
combination treatment
Fig. 1. Flow chart describing inclusion process.
27H.A. Hardarson et al. / Gynecologic Oncology Reports 11 (2015) 26–30
disease, one of which died within the 2 year follow-up. Of the two pa-
tients in the combined group, one has been without re-recurrence
while the other had incurable metastatic disease after 3.9 years.
All death eventswere related to re-recurrence except for one patient
who died from unrelated causes 2.2 years after successful treatment of
recurrent endometrial cancer. None of the patients in the surgical
group experienced re-recurrence or death during the two year follow-
up, but a single re-recurrence was seen after 2.3 years. This includes
deaths outside the 2 year follow-up.
Fig. 2 shows a Kaplan–Meier estimate for re-recurrence and Fig. 3
shows a Kaplan–Meier estimate for survival.
Table 3 shows the descriptive statistics conducted, 2 year re-
recurrence and survival rates andmean rates for recorded variables. Pa-
tient age in the different treatment groups is comparable. Body mass
index, which is known for 21 of the patients in the radiotherapy group
and 3 of the patients in the surgical group, was higher in the radiother-
apy group. None of the patients in the surgical group received adjuvant
chemotherapy treatment for the primary cancer. Three of thepatients in
the radiotherapy group had received adjuvant chemotherapy after
surgery for the primary cancer.
Univariate analysis of risk factors was calculated for both
re-recurrence and survival rate as outcome and results were BMI with
p-values of 0.56 (re-recurrence) and 0.57 (survival). Age p = 0.33 and
0.50, FIGO p = 0.60 and 0.63, Grade p = 0.41 and 0.13, myometrial
invasion p = 0.20 and 0.71, tumor size p = 0.51 and 0.48.
In our PubMed search we found no articles that dealt with the spe-
ciﬁc topic, survival and re-recurrence rate after resection of local recur-
rences of endometrial cancer in non-eradicated patients.
Table 1
Number of recurrences treated at our hospital each year in the study period.
Year Recurrences (included in our study)
2003 2 (2)
2004 5 (1)
2005 5 (1)
2006 7 (4)
2007 8 (1)
2008 4 (1)
2009 10 (3)
2010 22 (5)
2011 25 (7)
2012 30 (8)
Table 2
Data set of included patient characteristics.
Patient
number
Follow-up
time
Re-recurrence
eventa
Death
eventb
BMI Differentation
gradec
Myometrial
invasiond
FIGO
stagee
Tumor
sizef
Ageg Histological
typeh
Radiotherapy treatment
1 10.31 6.19 8.94 21.23 1 − 1A + 72 ED
2 9.35 3.11 7.23 27.51 2 − 1A − 80 ED
3 8.41 – – n/a 2 + 1B − 58 ED
4 7.76 0.88 2.79 27.14 2 + 1B − 79 ED
5 7.59 – 2.24 23.96 3 + 1B − 82 ED
6 11.09 2.97 3.08 n/a 1 − 1A − 78 ED
7 3.59 – – 28.53 1 + 1B − 78 ED
8 4.51 – – 22.66 2 + 1B − 77 ED
9 6.23 0.79 0.89 n/a 2 + 1B + 61 ED
10 7.7 2.11 7.11 27.95 1 − 1A + 78 ED
11 2.39 – – 18.99 3 + 1B + 68 ED
12 1.53 – – 23.62 2 + 1B − 69 ED
13 4.06 0a 3.16 26.44 2 + 3C − 67 ED
14 1.93 – – 57.16 1 − 1A + 58 ED
15 3.99 1.69 2.56 22.41 3 + 1B − 69 CS
16 2.46 – – 25.31 1 − 1A − 62 ED
17 4.14 – – 34.19 2 − 1A + 60 ED
18 2.4 – – 22.32 3 + 1B − 60 ED
19 2.02 – – 27.47 1 + 2 + 63 ED
20 2.31 – – 36.73 3 + 3A + 81 ED
21 2.41 – – n/a 2 − 1A − 52 ED
22 1.62 0.79 1.62 25.64 1 − 2 − 73 ED
23 1.39 – – 31.86 2 − 1A − 63 ED
24 2.07 0.91 1.89 35.16 3 − 1A + 72 CC
25 1.57 0.08 – 16 1 − 1A − 79 ED
26 2.22 0i 1.11 n/a 3 − 1A − 68 SA
Combined treatment
1 3.93 – – n/a 2 + 1C + 60 ED
2 6.78 3.93 – n/a 3 + 3A + 59 ED
Surgical treatment
1 4.61 – – 22.22 2 + 1B − 62 ED
2 4.16 – – n/a 3 + 3C − 84 CS
3 4.89 – – 22.77 2 − 1A + 80 ED
4 3.25 2.29 – 22.23 2 + 1B + 72 ED
5 2.47 – – n/a 2 − 1A − 80 ED
a Re-recurrence in years after recurrence.
b Death in years after recurrence, surviving patients as –.
c Differentiation grade is histological differentiation of endometrioid adenocarcinoma grade 1 as high differentiation to grade 3 low differentiation.
d At +invasion is through 50% of the wall,− less than.
e FIGO stage follows the 2009 revision
f Tumor size above 2 cm as +. Below 2 cm as−.
g Age at the time of primary cancer diagnosis.
h ED = endometrioid adenocarcinoma. CS = carcinosarcoma. CC = clear cell carcinoma. SA = serous adenocarcinoma.
i Were never cured of their recurrence.
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Discussion
This study is to our knowledge the ﬁrst to investigate and describe
differences in outcome in non-irradiated patients with central recur-
rence of endometrial cancer treatedwith either radiotherapy or surgery.
The study describes the treatment and outcomes for 33 patients with
vaginal vault recurrences and the results indicate that surgical removal
of the recurrence is an effective treatment.
Our description of a cohort that is naive to radiotherapy makes the
study unique and very relevant regarding future choice of treatment.
Firstly, the use of adjuvant radiotherapy in the primary treatment of
endometrial cancer has been scaled down in many countries in the
recent years, so in the future the majority of patients with recurrent
disease will be non-irradiated.
Furthermore it is important to focus on research regarding treat-
ment of speciﬁcally vaginal vault recurrences, as this is the most preva-
lent type of recurrence in a non-irradiated population (Creutzberg et al.,
2011; Group et al., 2009; Keys et al., 2004).
Studies on surgical treatment
Previous studies regarding surgical treatment of recurrent endome-
trial cancer are few and differ from the studies that describe recurrences
treatedwith radiotherapy.Weassume it ismainly because radiotherapy
has been the ﬁrst line of treatment for locally recurrent disease for the
last decades (Creutzberg et al., 2011; Huh et al., 2007; Jhingran et al.,
2003). Surgery has mostly been used when the extent of the disease
or other factors indicated that radiotherapy could not be curative
(Huh et al., 2007; Keys et al., 2004; Awtrey et al., 2006; Barakat et al.,
1999; Khoury-Collado et al., 2012; Berek et al., 2005; Bristow et al.,
2006; Campagnutta et al., 2004). Therefore, the studies reviewing surgi-
cal treatments are historically focused on total pelvic exenteration as a
potentially curative treatment for advanced recurrent disease in thepel-
vis (Barakat et al., 1999). More recently less radical surgical approaches
to the same disease have been studied by Awtrey et al. (2006) In both
investigations most of the study population are irradiated patients, in
which case radiotherapy is known to be less effective and with a
much higher complication rate, but patients are also selected due to
local metastasis into neighboring organs or large tumor mass. Unsur-
prisingly the survival rate for patients with advanced disease is lower
than in patients treated for isolated local recurrences, with a 5 year sur-
vival rate of 20–45% (Barakat et al., 1999; Morris et al., 1996).
Therefore, these studies are not directly comparable to the results for
patients treated surgically in our study. However they present ﬁndings
that we have used to design this study. One is that the location of the
recurrence is an important prognostic factor, where vaginal vault recur-
rences have a signiﬁcantly better outcome than recurrences located
elsewhere (Awtrey et al., 2006; Bristow et al., 2006; Campagnutta
et al., 2004). Another is that tumor diameter is of importance, as a small-
er tumor size indicates better outcome (van Wijk et al., 2009). It has
been found that tumor size below 2 cm3 indicates a better outcome,
which prompted us to use the same demarcation to stratify for tumor
size in this study. We did however not ﬁnd any signiﬁcant difference
based on tumor size.
Studies on radiotherapy
Radiotherapy used as adjuvant treatment for primary endometrial
cancer and also as a primary treatment of local recurrent endometrial
cancer has a long history (van Wijk et al., 2009). In particular the use
of adjuvant radiotherapy is common in many countries for certain
stages and histologic types/grades of endometrial cancer (Creutzberg
et al., 2011; van Wijk et al., 2009; Group et al., 2009; Keys et al., 2004;
Ackerman et al., 1996). However, in the last two decades several large
randomized studies examining the effects of adjuvant radiotherapy in
the treatment endometrial cancer, partially prompted by ﬁndings by
Ackerman et al. (1996) have been conducted. In a retrospective study
they found no survival beneﬁt for adjuvant radiotherapy despite reduc-
tion in recurrence rate. This led to the PORTEC trial, ASTEC trial, GOG
trial and the NCIC GTC EN5 trials that convincingly showed that long
term survival was not improved by adjuvant radiotherapy in low to in-
termediary risk endometrial cancers (Creutzberg et al., 2011; Group
et al., 2009; Keys et al., 2004). One reason is that complete cure of locally
recurrent disease was achieved in a larger percentage in the non-
irradiated population (in the PORTEC study 5 year survival rates after
vaginal recurrence were 70% in the non-irradiated group versus 38%
in the irradiated group) (Creutzberg et al., 2011). Another reason
is that recurrent disease in irradiated patients was more like to be
non-local (Creutzberg et al., 2011; Group et al., 2009; Keys et al., 2004).Fig. 3.KaplanMeier overall survival curves of all included patients by treatmentmodality.
Table 3
Comparison of treatment modalities.
Radiotherapy group Surgical group
2 Year re-recurrence ratea 40% (95% CI 9.2%–48%) 0% (95% CI 0%–60%)b
P value = 0.2981. 95
2 Year survival ratea 83% (95% CI 71%–100%) 100% (95% CI 40%–100%)b
P value = 1.00
Mean (SD) Mean (SD)
Follow up time 4.42 years (2.99) 3.88 years (0.90)
BMI 27.7 (8.29) 22.4 (0.26)
Age 69.5 years (8.44) 69.5 years (7.84)
a Calculated using ﬁshers exact test, the two-sided P value estimated using themethod
of summing small P values.
b Estimated using rule of three.
Fig. 2. Kaplan Meier estimate of re-recurrence-free rate of all included patients by treat-
ment modality.
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The ﬁndings in our radiotherapy group show a survival rate compa-
rable to what is found in the previous studies on survival after radio-
therapy treatment of recurrent endometrial cancer, with 83% after 2
years. (Creutzberg et al., 2011; Group et al., 2009; Keys et al., 2004;
Ackerman et al., 1996).
Our study has a relatively shortmean follow-up time. This is because
most of the patients diagnosedwith a recurrent disease at OUHwere di-
agnosed in the years 2010–2012, and fewer in the preceding years. The
main reason is that within the study period gynecologic cancer treat-
ment has been centralized from many smaller hospitals to ﬁve highly
specialized centers in Denmark, one of which is OUH, with the effect
that many more patients were treated at the center per year after
2010. The number of patients with recurrent disease treated at OUH
per year can be seen in Table 1.
There are limiting factors regarding the nature of retrospective stud-
ies like this, and we cannot completely account for a possible selection
bias that can have inﬂuenced which patients received radiotherapy
and which received surgical treatment. We found that the mean BMI
was higher in the radiotherapy group by 5 points, which indicates that
patients with higher BMI were selected for radiotherapy rather than
surgical treatment, but the difference was not statistically signiﬁcant.
We also found that there were no statistically signiﬁcant differences in
tumor size, age, differentiation grade or FIGO stage.
About 80% of all endometrial carcinomas are of the endometrioid
type, which generally have a more favorable prognosis than tumors
with type 2 histology (Danish Gynecological Cancer Group D, 2010).
With 23 endometrioid adenocarcinomas and 3 non-endometrioid carci-
nomas (see exact type in Table 2) in the radiotherapy group and 4
endometrioid adenocarcinomas and 1 carcinosarcoma in the surgical
treatment group, we found no statistically signiﬁcant difference in his-
tology in the two groups. Those treated with a combination treatment
both had endometrioid adenocarcinoma.
With no deaths during the follow-up in the surgical group and just
one re-recurrence in a woman 2.3 years after the primary recurrence,
the results of surgery-only are encouraging. The small sample size and
relatively short follow up period limit the statistical signiﬁcance of the
results andmakes it impossible to doweighted analysis of thedata. Nev-
ertheless, the results indicate that the surgical treatment of locally re-
current endometrial cancer is a valid and effective treatment method
and worth further investigations. It will be important to reexamine pa-
tient data in a few years, when more follow-up time has elapsed.
Having more than one documented effective treatment for locally
recurrent endometrial cancer is of course highly beneﬁcial and it should
warrant larger studies on the efﬁcacy of surgical treatment versus radio-
therapy, preferably in randomized trials. If surgical treatment is compa-
rable to radiotherapy in survival, other outcome factors such as
complications and quality of life need to be evaluated further.
Conﬂict of interest statement
The authors declare no competing interests.
References
Ackerman, I., et al., 1996. Endometrial carcinoma — relative effectiveness of adjuvant
irradiation vs therapy reserved for relapse. Gynecol. Oncol. 60 (2), 177–183.
Amant, F., et al., 2005. Endometrial cancer. Lancet 366 (9484), 491–505.
Awtrey, C.S., et al., 2006. Surgical resection of recurrent endometrial carcinoma. Gynecol.
Oncol. 102 (3), 480–488.
Barakat, R.R., et al., 1999. Pelvic exenteration for recurrent endometrial cancer. Gynecol.
Oncol. 75 (1), 99–102.
Berek, J.S., et al., 2005. Pelvic exenteration for recurrent gynecologic malignancy: survival
and morbidity analysis of the 45-year experience at UCLA. Gynecol. Oncol. 99 (1),
153–159.
Bristow, R.E., et al., 2006. Salvage cytoreductive surgery for recurrent endometrial cancer.
Gynecol. Oncol. 103 (1), 281–287.
Campagnutta, E., et al., 2004. Surgical treatment of recurrent endometrial carcinoma.
Cancer 100 (1), 89–96.
Cancer W.I.A.F.R.O., 2012. GLOBOCAN 2012: estimated cancer incidence, mortality and
prevalence worldwide in 2012.
Creutzberg, C.L., et al., 2011. Fifteen-year radiotherapy outcomes of the randomized
PORTEC-1 trial for endometrial carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 81 (4),
e631–e638.
Danish Gynecological Cancer Group D, 2010. Guidelines for visitation, diagnostics, treat-
ment and control of cancer corporis uteri.
Gredmark, T., et al., 1995. Histopathological ﬁndings in women with postmenopausal
bleeding. Br. J. Obstet. Gynaecol. 102 (2), 133–136.
Group, A.E.S., et al., 2009. Adjuvant external beam radiotherapy in the treatment of
endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled
trial results, systematic review, and meta-analysis. Lancet 373 (9658), 137–146.
Huh, W.K., et al., 2007. Salvage of isolated vaginal recurrences in women with surgical
stage I endometrial cancer: a multiinstitutional experience. Int. J. Gynecol. Cancer
17 (4), 886–889.
Jhingran, A., Burke, T.W., Eifel, P.J., 2003. Deﬁnitive radiotherapy for patients with isolated
vaginal recurrence of endometrial carcinoma after hysterectomy. Int. J. Radiat. Oncol.
Biol. Phys. 56 (5), 1366–1372.
Keys, H.M., et al., 2004. A phase III trial of surgerywith orwithout adjunctive external pelvic
radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic
Oncology Group study. Gynecol. Oncol. 92 (3), 744–751.
Khoury-Collado, F., et al., 2012. Pelvic exenteration with curative intent for recurrent
uterine malignancies. Gynecol. Oncol. 124 (1), 42–47.
Morris, M., et al., 1996. Treatment of recurrent adenocarcinoma of the endometriumwith
pelvic exenteration. Gynecol. Oncol. 60 (2), 288–291.
vanWijk, F.H., et al., 2009. Management of recurrent endometrioid endometrial carcinoma:
an overview. Int. J. Gynecol. Cancer 19 (3), 314–320.
30 H.A. Hardarson et al. / Gynecologic Oncology Reports 11 (2015) 26–30
